Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.

about

DDX23-Linc00630-HDAC1 axis activates the Notch pathway to promote metastasis

P2860

Q33889017-CFADA851-DD74-42D8-AED7-3BB674187FA5

P2860

Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.

Item

http://www.wikidata.org/entity/Q39063642

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Utilization Patterns and Trend ...... gnosed Metastatic Lung Cancer.

@en

Utilization Patterns and Trends in Epidermal Growth Factor Receptor

@nl

type

Item

label

Utilization Patterns and Trend ...... gnosed Metastatic Lung Cancer.

@en

Utilization Patterns and Trends in Epidermal Growth Factor Receptor

@nl

prefLabel

Utilization Patterns and Trend ...... gnosed Metastatic Lung Cancer.

@en

Utilization Patterns and Trends in Epidermal Growth Factor Receptor

@nl

P1476

Utilization Patterns and Trend ...... gnosed Metastatic Lung Cancer.

@en

P2093

Bo Zhao

http://www.w3.org/2001/XMLSchema#string

Chan Shen

http://www.w3.org/2001/XMLSchema#string

George R Simon

http://www.w3.org/2001/XMLSchema#string

Kenneth L Kehl

http://www.w3.org/2001/XMLSchema#string

Shouhao Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

ROS1 rearrangements define a unique molecular class of lung cancers.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

e233-e241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLLC.2016.11.002

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sharon H. Giordano

P577

2016-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28024927

http://www.w3.org/2001/XMLSchema#string

P932

5903454

http://www.w3.org/2001/XMLSchema#string

Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.

about

P2860

P2860

Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932